-transparent.png){kind=logo}
Captopril was tested for pharmacokinetics. Its hypotensive effect was compared with plasma renin activity (PRA) and blood captopril levels in single and prolonged administrations of its various doses in 58 hypertensive patients. When a single dose (25 mg) of captopril was given, a relationship was found between its hypotensive effect and higher blood concentration, baseline PRA. The detection rate of its antihypertensive effect was not related to the baseline PRA. The efficient and safe dose of captopril was shown to be 75-150 mg daily, maintaining its blood concentration within ranges of 75-175 ng/ml.
Related Publications
V G Kukes, and
Sh N Nasyrov, and
V I Volchenok, and
E A Toporova, and
T A Abdunazarov
January 1986,
Nephron,
V G Kukes, and
Sh N Nasyrov, and
V I Volchenok, and
E A Toporova, and
T A Abdunazarov
January 1988,
Acta physiologica Hungarica,
V G Kukes, and
Sh N Nasyrov, and
V I Volchenok, and
E A Toporova, and
T A Abdunazarov
January 1995,
Klinicheskaia meditsina,
V G Kukes, and
Sh N Nasyrov, and
V I Volchenok, and
E A Toporova, and
T A Abdunazarov
April 1999,
Journal of cardiovascular pharmacology and therapeutics,
V G Kukes, and
Sh N Nasyrov, and
V I Volchenok, and
E A Toporova, and
T A Abdunazarov
January 1985,
Journal of cardiovascular pharmacology,
V G Kukes, and
Sh N Nasyrov, and
V I Volchenok, and
E A Toporova, and
T A Abdunazarov
May 2013,
Clinical pharmacokinetics,
V G Kukes, and
Sh N Nasyrov, and
V I Volchenok, and
E A Toporova, and
T A Abdunazarov
November 2009,
International journal of clinical pharmacology and therapeutics,
V G Kukes, and
Sh N Nasyrov, and
V I Volchenok, and
E A Toporova, and
T A Abdunazarov
March 2020,
Clinical pharmacokinetics,
V G Kukes, and
Sh N Nasyrov, and
V I Volchenok, and
E A Toporova, and
T A Abdunazarov
January 1992,
European journal of clinical pharmacology,
V G Kukes, and
Sh N Nasyrov, and
V I Volchenok, and
E A Toporova, and
T A Abdunazarov
May 1988,
Journal of clinical pharmacology,
